MicardisPlus 40 mg/12.5 mg tablets
- Name:
MicardisPlus 40 mg/12.5 mg tablets
- Company:
Boehringer Ingelheim Limited
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may be renewed (B)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/12/18
(Click to Download)Click on this link to Download PDF directly
Boehringer Ingelheim Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 20 December 2018 PIL
Reasons for updating
- Change to section 6 - date of revision
Updated on 18 December 2018 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The only update to the previous versions, implemented on 04 December 2018, is to section 10 date of revision
Updated on 6 December 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
- Correction of spelling/typing errors
Updated on 5 December 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Sections 4.4, 4.8 and 5.1 of the SmPCs have been updated. In addition a minor editorial update has been made to the section 4.8 AE reporting details. A minor correction has also been made to the SmPC title for the 40 mg/12.5 mg and 80 mg/12/5 mg tablets.
Section 10, date of revision of the text has been updated
Updated on 11 July 2018 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 10 July 2018 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 9 - Date of first authorisation/renewal of the authorisation
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 10 August 2017 PIL
Reasons for updating
- New PIL for new product
Updated on 10 August 2017 PIL
Reasons for updating
- Improved presentation of PIL
Updated on 1 June 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - how to take/use
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Change to other sources of information section
Updated on 30 May 2017 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may be renewed (B)
Updated on 30 May 2017 SmPC
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 3 - Pharmaceutical form
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
- Change from individual to joint SPC
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
-Sections 1, 2, 3, 4.1, 8 updated as a result of merging the 40/12.5 mg and 80 mg/12.5 mg SPCs
-Sections updated in line with CCDS 0252-11 4.2, 4.4, 4.5, 4.7, 4.8, 5.1, 5.2, 6.6.
4.2, 4.5, 4.8, 5.1 (Clarification of sub-headings and minor editorial clarifications)
4.4 (update to contraindication for patients with severe renal impairment)
4.5 (Detail added regarding interactions with Calcium salts)
4.7 (Clarification of instructions on driving and use machines)
4.8 (Hydrochlorothiazide adverse reactions frequencies revised for: Thrombocytopenia, hypomagnesaemia, hypercalcaemia, hypochloraemic alkalosis, headache, nausea, erythema multiforme)
5.1 (Section rearranged with revised sub-headings)
Paediatric population detail added
5.2 (Details regarding Linearity/non-linearity updated)
6.6 (Updated disposal instructions)
-Section 4.8 was updated to include the revised adverse drug reaction reporting Maltese address.
-Sections 2 Typographical change
-Section 10 revision date updated in line with PO (06Apr17).
Updated on 3 October 2016 PIL
Reasons for updating
- Change of contraindications
- Change to instructions about overdose
- Change to side-effects
- Change to information about drinking alcohol
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 24 September 2014 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 24 September 2014 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
The SPCs have been updated to been revised to take into account the updated wording for concomitant use with ARBs or aliskiren in the contraindication, warning and interactions section of SPC following conclusion of the EU Art 31 Referral Procedure on RAS acting agents – class labelling request (ref EMEA-H-A-31-1370). Date of EC decision is 4 September 2014 with final text being available 10 September. Sections affected are 4.2, 4.3, 4.4, 4.5 also with revision to 5.1. In addition, in section 4.8 the Irish Authority contact details for Adverse Event reporting have been revised following the recent authority name change. Date of revision has also been updated to September 2014.
Further to the above, an error has been corrected within Section 4.8 regarding the frequency of hyperkalaemia together with an additional minor/editorial update. These changes were made to align with the final approved texts and impact the 40/12.5 mg and 80/12.5 mg strength only.
Updated on 4 December 2013 PIL
Reasons for updating
- Change to further information section
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 4 December 2013 SmPC
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.8 Undesirable Effects
New text regarding the reporting of suspected adverse reactions in the UK, Ireland and Malta has been added at the end of this section. In total, four new paragraphs have been added.
Section 5.1 Pharmacodynamic Properties
A new sub-heading (and corresponding text) regarding Cardiovascular prevention has been added to this section. In total, 7 new paragraphs have been added.
The previous text of The effects of telmisartan on mortality and cardiovascular morbidity are currently unknown has been deleted from this section. The text was previously located between the In the “Prevention Regimen for Effectively avoiding Second Strokes” … and Hydrochlorothiazide is a thiazide diuretic … paragraphs.
Section 10 Date of Revision of the Text
The date has been amended from May 2013 to October 2013.
Updated on 26 June 2013 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to storage instructions
- Change to drug interactions
- Change to further information section
- Change to date of revision
Updated on 21 June 2013 SmPC
Reasons for updating
- Addition of separate SPCs covering individual presentations
Legal category: Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 December 2012 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 11 July 2012 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to storage instructions
- Change to side-effects
- Change to drug interactions
- Change to information about pregnancy or lactation
- Change to information about driving or using machinery
- Change to further information section
- Change to date of revision
- Change to dosage and administration
- Change to MA holder contact details
Updated on 15 February 2012 PIL
Reasons for updating
- Change of manufacturer
- Change to date of revision
Updated on 19 July 2011 PIL
Reasons for updating
- Change to MA holder contact details
- Change to name of manufacturer
Updated on 4 June 2010 PIL
Reasons for updating
- Change to side-effects
- Change to further information section
Updated on 8 May 2010 PIL
Reasons for updating
- Change to side-effects
Updated on 9 June 2009 PIL
Reasons for updating
- Improved electronic presentation
Updated on 11 September 2008 PIL
Reasons for updating
- Improved electronic presentation
Updated on 11 September 2007 PIL
Reasons for updating
- Improved electronic presentation
Updated on 12 June 2006 PIL
Reasons for updating
- New PIL for medicines.ie